Hepatic Oncology最新文献_第5页

JAK/STAT signaling in hepatocellular carcinoma. JAK/STAT信号在肝细胞癌中的作用。

IF 5

Hepatic Oncology Pub Date : 2020-03-18 DOI: 10.2217/hep-2020-0001

Justin Jit Hin Tang, Dexter Kai Hao Thng, Jhin Jieh Lim, Tan Boon Toh

引用次数: 63

The role of the innate immune system in the development and treatment of hepatocellular carcinoma. 先天免疫系统在肝细胞癌发展和治疗中的作用。

IF 5

Hepatic Oncology Pub Date : 2020-01-31 DOI: 10.2217/hep-2019-0007

Christoph Roderburg, Alexander Wree, Münevver Demir, Moritz Schmelzle, Frank Tacke

引用次数: 44

Updates of colorectal cancer liver metastases therapy: review on DEBIRI. 结直肠癌肝转移治疗进展:DEBIRI综述。

IF 5

Hepatic Oncology Pub Date : 2020-01-21 DOI: 10.2217/hep-2019-0010

Giammaria Fiorentini, Donatella Sarti, Roberto Nani, Camillo Aliberti, Caterina Fiorentini, Stefano Guadagni

引用次数: 28

Cytoplasmic translocation of nuclear LSD1 (KDM1A) in human hepatoma cells is induced by its inhibitors. 核LSD1 (KDM1A)在人肝癌细胞中的细胞质易位是由其抑制剂诱导的。

IF 5

Hepatic Oncology Pub Date : 2019-06-05 DOI: 10.2217/hep-2018-0008

Suemi Yabuta, Yoshihiro Shidoji

引用次数: 7

The evolving landscape of precision medicine in primary liver cancer. 原发性肝癌精准医学的发展前景。

IF 5

Hepatic Oncology Pub Date : 2019-06-04 DOI: 10.2217/hep-2019-0004

Sean P Martin, Xin Wei Wang

{"title":"The evolving landscape of precision medicine in primary liver cancer.","authors":"Sean P Martin, Xin Wei Wang","doi":"10.2217/hep-2019-0004","DOIUrl":"https://doi.org/10.2217/hep-2019-0004","url":null,"abstract":"The incidence of primary liver cancer (PLC) is rising faster than any other malignancy in the USA and is estimated to result in over 31,000 deaths in 2019 [1]. PLC poses a unique challenge in that the majority of patients suffer from both their malignancy and underlying liver damage which is the inciting factor for their hepatocarcinogenesis. Viral infections such as Hepatitis B and C, lifestyle choices such as heavy alcohol use and inherited genetic disorders such as primary biliary cirrhosis can all lead to underlying liver cirrhosis leaving the patient vulnerable to malignancy and without aggressive treatment options. There are multiple histologic subtypes which comprise PLC but by far the two most common are hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). Interestingly, while historically treated as two distinct malignancies, there is a growing body of evidence that they may be more alike than previously thought. Classically it was believed that iCCA arose from cholangiocytes, and while the origins of HCC remained more elusive it was hypothesized that hepatic stem cells in addition to hepatocytes were implicated. More recent work reveals that both malignancies could originate from hepatocytes and more strikingly, in certain subsets of patients, share a common molecular subtype [2–4]. These commonalities shed light on the potential drivers of hepatocarcinogenesis and are the first steps of novel targeted therapies. With a more thorough understanding of these tumors, directed personalized care is possible.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"6 2","pages":"HEP12"},"PeriodicalIF":5.0,"publicationDate":"2019-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2019-0004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37075028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Current options and future possibilities for the systemic treatment of hepatocellular carcinoma. 肝细胞癌系统治疗的当前选择和未来可能性。

IF 5

Hepatic Oncology Pub Date : 2019-06-04 DOI: 10.2217/hep-2019-0001

Jean-Luc Raoul, Jean-Sébastien Frenel, Judith Raimbourg, Marine Gilabert

引用次数: 28

Journal Watch: Dr Tu looks back at the most important research articles released in 2018 relating to models and biomarkers of hepatocellular carcinoma. 期刊观察:屠博士回顾了2018年发表的与肝细胞癌模型和生物标志物相关的最重要的研究文章。

IF 5

Hepatic Oncology Pub Date : 2019-02-12 eCollection Date: 2019-03-01 DOI: 10.2217/hep-2019-0002

Thomas Tu

{"title":"Journal Watch: Dr Tu looks back at the most important research articles released in 2018 relating to models and biomarkers of hepatocellular carcinoma.","authors":"Thomas Tu","doi":"10.2217/hep-2019-0002","DOIUrl":"https://doi.org/10.2217/hep-2019-0002","url":null,"abstract":"Wang G, Chow RD, Ye L et al. Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR-mediated direct in vivo screening. Sci. Adv. 4(2), eaao5508 (2018). Multiple putative hepatocellular carcinoma (HCC) driver mutations have been identified using next-generation sequencing, but the majority have not been confirmed in in vivo settings or in combination with each other. Wang et al. describe a high-throughput solution by transducing transgenic mice containing a Cre-dependent Cas9 with hepatocyte-specific adeno-associated virus vectors that encode for Cre recombinase, EGFP and a sgRNA from a library, targeting HCC candidate genes (49 genes drawn from online databases). Indels at target loci were then confirmed and quantified using multiplexed molecular inversion probe sequencing. Within 3 months of transduction, mice developed multifocal GFP-positive HCC, in which significant enrichment of Trp53, Setd2, Cic and Pik3R1 mutations were observed. Several pairs of mutations were significantly enriched, including Cdkn2a and Pten, B2m and Kansl1, and Arid2 and Cdkn2a. This exciting novel HCC model has the potential to confirm thousands of gene candidates identified by sequencing projects.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"6 1","pages":"IJE10"},"PeriodicalIF":5.0,"publicationDate":"2019-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2019-0002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37061083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum. 勘误表。

IF 5

Hepatic Oncology Pub Date : 2018-12-21 DOI: 10.2217/hep-2017-0017c1

引用次数: 0

Hepatocellular carcinoma treatment: hurdles, advances and prospects. 肝细胞癌治疗：障碍、进展和前景。

IF 1.2

Hepatic Oncology Pub Date : 2018-09-28 eCollection Date: 2018-04-01 DOI: 10.2217/hep-2018-0002

Ratna Kumari, Manoj Kumar Sahu, Anindita Tripathy, Kanishka Uthansingh, Manas Behera

{"title":"Hepatocellular carcinoma treatment: hurdles, advances and prospects.","authors":"Ratna Kumari, Manoj Kumar Sahu, Anindita Tripathy, Kanishka Uthansingh, Manas Behera","doi":"10.2217/hep-2018-0002","DOIUrl":"10.2217/hep-2018-0002","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is one of the major causes of cancer-related mortality and is particularly refractory to the available chemotherapeutic drugs. Among various etiologies of HCC, viral etiology is the most common, and, along with alcoholic liver disease and nonalcoholic steatohepatitis, accounts for almost 90% of all HCC cases. HCC is a heterogeneous tumor associated with multiple signaling pathway alterations and its complex patho-physiology has made the treatment decision challenging. The potential curative treatment options are effective only in small group of patients, while palliative treatments are associated with improved survival and quality of life for intermediate/advanced stage HCC patients. This review article focuses on the currently available treatment strategies and hurdles encountered for HCC therapy. The curative treatment options discussed are surgical resection, liver transplantation, and local ablative therapies which are effective for early stage HCC patients. The palliative treatment options discussed are embolizing therapies, systemic therapies, and molecular targeted therapies. Besides, the review also focuses on hurdles to be conquered for successful treatment of HCC and specifies the future prospects for HCC treatment. It also discusses the multi-modal approach for HCC management which maximizes the chances of better clinical outcome after treatment and identifies that selection of a particular treatment regimen based on patients' disease stage, patients' ages, and other underlying factors will certainly lead to a better prognosis.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"5 2","pages":"HEP08"},"PeriodicalIF":1.2,"publicationDate":"2018-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0e/98/hep-05-08.PMC6613045.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37415966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review. 经导管动脉化疗栓塞联合射频或微波消融治疗肝细胞癌:综述。

IF 5

Hepatic Oncology Pub Date : 2018-09-28 eCollection Date: 2018-04-01 DOI: 10.2217/hep-2018-0001

Nikolaos Galanakis, Elias Kehagias, Nikolas Matthaiou, Dimitrios Samonakis, Dimitrios Tsetis

引用次数: 23